36 related articles for article (PubMed ID: 21618353)
21. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
Martín-de-Carpi J; Pociello N; Varea V
J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
[TBL] [Abstract][Full Text] [Related]
22. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
23. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
Riis A; Martinsen TC; Waldum HL; Fossmark R
Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
[TBL] [Abstract][Full Text] [Related]
24. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
[TBL] [Abstract][Full Text] [Related]
25. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.
Doecke JD; Hartnell F; Bampton P; Bell S; Mahy G; Grover Z; Lewindon P; Jones LV; Sewell K; Krishnaprasad K; Prosser R; Marr D; Fischer J; R Thomas G; Tehan JV; Ding NS; Cooke SE; Moss K; Sechi A; De Cruz P; Grafton R; Connor SJ; Lawrance IC; Gearry RB; Andrews JM; Radford-Smith GL;
Aliment Pharmacol Ther; 2017 Feb; 45(4):542-552. PubMed ID: 27995633
[TBL] [Abstract][Full Text] [Related]
26. Long-term durability of response to adalimumab in Crohn's disease.
Chaparro M; Panés J; García V; Merino O; Nos P; Domènech E; Peñalva M; García-Planella E; Esteve M; Hinojosa J; Andreu M; Muñoz F; Gutiérrez A; Mendoza JL; Barrio J; Barreiro-de M; Vera I; Vilar P; Cabriada JL; Montoro MA; Aldeguer X; Saro C; Gisbert JP
Inflamm Bowel Dis; 2012 Apr; 18(4):685-90. PubMed ID: 21618353
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy and safety of Adalimumab in Crohn's disease].
Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
[TBL] [Abstract][Full Text] [Related]
28. A practical, evidence-based guide to the use of adalimumab in Crohn's disease.
Rubin DT; Panaccione R; Chao J; Robinson AM
Curr Med Res Opin; 2011 Sep; 27(9):1803-13. PubMed ID: 21809894
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.
Paul S; Moreau AC; Del Tedesco E; Rinaudo M; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
Inflamm Bowel Dis; 2014 Jul; 20(7):1288-95. PubMed ID: 24831559
[TBL] [Abstract][Full Text] [Related]
30. [New therapeutic strategy for patients with Crohn's disease using of adalimumab].
Motoya S; Yamashita M; Tanaka H
Nihon Shokakibyo Gakkai Zasshi; 2012 Mar; 109(3):370-7. PubMed ID: 22398901
[No Abstract] [Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
